May 18 (Reuters) - ProMetic Life Sciences Inc Says To
Commence Clinical Trial Of Its Orally Active Anti
* Says to commence clinical trial of its orally active
anti-fibrotic lead drug candidate, PBI-4050
* Phase 2 clinical trial of PBI-4050 to commence in Q2 2016
as planned
* Health Canada authorizes ProMetic to proceed with its
PBI-4050 clinical trial in patients with cystic fibrosis
Source text for Eikon: ID:nCNWKdYrla
Further company coverage: PLI.TO
(Bengaluru Newsroom: +1 646 223 8780)